Hanmi Pharm. Co., Ltd. (128940.KS)
KRW 269500.0
(-1.46%)
KRW 269500.0
(-1.46%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 851.82 Billion KRW | -6.94% |
| 2022 | 915.35 Billion KRW | -9.23% |
| 2021 | 1008.46 Billion KRW | -3.97% |
| 2020 | 1050.13 Billion KRW | -3.78% |
| 2019 | 1091.44 Billion KRW | 21.01% |
| 2018 | 901.95 Billion KRW | 3.85% |
| 2017 | 868.5 Billion KRW | 0.7% |
| 2016 | 862.45 Billion KRW | -11.8% |
| 2015 | 977.78 Billion KRW | 120.18% |
| 2014 | 444.08 Billion KRW | 6.25% |
| 2013 | 417.95 Billion KRW | -1.95% |
| 2012 | 426.24 Billion KRW | 4.08% |
| 2011 | 409.52 Billion KRW | -3.03% |
| 2010 | 422.34 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 756.21 Billion KRW | -6.1% |
| 2024 Q1 | 805.35 Billion KRW | -5.46% |
| 2023 Q4 | 851.82 Billion KRW | 5.71% |
| 2023 Q1 | 927.6 Billion KRW | 1.34% |
| 2023 FY | 851.82 Billion KRW | -6.94% |
| 2023 Q3 | 805.78 Billion KRW | -0.7% |
| 2023 Q2 | 811.43 Billion KRW | -12.52% |
| 2022 Q4 | 915.35 Billion KRW | -5.13% |
| 2022 FY | 915.35 Billion KRW | -9.23% |
| 2022 Q1 | 1029.01 Billion KRW | 2.04% |
| 2022 Q2 | 967.3 Billion KRW | -6.0% |
| 2022 Q3 | 964.9 Billion KRW | -0.25% |
| 2021 Q2 | 1058.86 Billion KRW | -2.52% |
| 2021 Q1 | 1086.27 Billion KRW | 3.44% |
| 2021 Q3 | 1041.34 Billion KRW | -1.65% |
| 2021 FY | 1008.46 Billion KRW | -3.97% |
| 2021 Q4 | 1008.46 Billion KRW | -3.16% |
| 2020 Q3 | 1139.32 Billion KRW | 0.04% |
| 2020 Q2 | 1138.9 Billion KRW | -0.45% |
| 2020 FY | 1050.13 Billion KRW | -3.78% |
| 2020 Q1 | 1144.07 Billion KRW | 4.82% |
| 2020 Q4 | 1050.13 Billion KRW | -7.83% |
| 2019 Q2 | 1072.76 Billion KRW | 2.03% |
| 2019 FY | 1091.44 Billion KRW | 21.01% |
| 2019 Q4 | 1091.44 Billion KRW | -1.02% |
| 2019 Q3 | 1102.67 Billion KRW | 2.79% |
| 2019 Q1 | 1051.44 Billion KRW | 16.57% |
| 2018 Q4 | 901.95 Billion KRW | -4.56% |
| 2018 Q3 | 945.04 Billion KRW | -0.96% |
| 2018 Q2 | 954.2 Billion KRW | 5.47% |
| 2018 FY | 901.95 Billion KRW | 3.85% |
| 2018 Q1 | 904.71 Billion KRW | 4.17% |
| 2017 Q4 | 868.5 Billion KRW | 3.1% |
| 2017 FY | 868.5 Billion KRW | 0.7% |
| 2017 Q2 | 779.06 Billion KRW | 5.77% |
| 2017 Q3 | 842.38 Billion KRW | 8.13% |
| 2017 Q1 | 736.53 Billion KRW | -14.6% |
| 2016 Q2 | 767.42 Billion KRW | -7.04% |
| 2016 Q4 | 862.45 Billion KRW | 15.36% |
| 2016 Q3 | 747.64 Billion KRW | -2.58% |
| 2016 FY | 862.45 Billion KRW | -11.8% |
| 2016 Q1 | 825.52 Billion KRW | -15.57% |
| 2015 Q3 | 581.56 Billion KRW | 13.22% |
| 2015 Q1 | 452.8 Billion KRW | 1.96% |
| 2015 Q2 | 513.64 Billion KRW | 13.44% |
| 2015 FY | 977.78 Billion KRW | 120.18% |
| 2015 Q4 | 977.78 Billion KRW | 68.13% |
| 2014 Q1 | 412.79 Billion KRW | -1.24% |
| 2014 FY | 444.08 Billion KRW | 6.25% |
| 2014 Q2 | 424.01 Billion KRW | 2.72% |
| 2014 Q4 | 444.08 Billion KRW | 3.46% |
| 2014 Q3 | 429.22 Billion KRW | 1.23% |
| 2013 Q4 | 417.95 Billion KRW | 2.53% |
| 2013 Q2 | 425.11 Billion KRW | -0.06% |
| 2013 FY | 417.95 Billion KRW | -1.95% |
| 2013 Q1 | 425.35 Billion KRW | -0.21% |
| 2013 Q3 | 407.64 Billion KRW | -4.11% |
| 2012 FY | 426.24 Billion KRW | 4.08% |
| 2012 Q2 | 464.98 Billion KRW | 2.95% |
| 2012 Q3 | 446.04 Billion KRW | -4.07% |
| 2012 Q4 | 426.24 Billion KRW | -4.44% |
| 2012 Q1 | 451.63 Billion KRW | 0.0% |
| 2011 Q2 | 373.41 Billion KRW | -3.81% |
| 2011 Q3 | 367.16 Billion KRW | -1.67% |
| 2011 FY | 409.52 Billion KRW | -3.03% |
| 2011 Q1 | 388.2 Billion KRW | 0.0% |
| 2010 Q3 | 380.58 Billion KRW | 0.0% |
| 2010 FY | 422.34 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -994.076% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 8.386% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | -20.468% |
| HANDOK Inc. | 449.7 Billion KRW | -89.418% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -894.305% |
| Yuhan Corporation | 712.33 Billion KRW | -19.582% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | -34.801% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -5259.245% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -1491.344% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -313.757% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -1033.183% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -476.358% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -1109.956% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -994.076% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -2237.849% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | -239.168% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | -285.956% |
| JW Holdings Corporation | 827.51 Billion KRW | -2.938% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | -94.928% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | -45.166% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -124.402% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -974.159% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -1117.455% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | -250.758% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | -157.899% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -994.076% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | -73.835% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 0.723% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -124.402% |
| Yuhan Corporation | 712.33 Billion KRW | -19.582% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | -78.276% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -521.913% |
| Suheung Co., Ltd. | 516.66 Billion KRW | -64.869% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -124.402% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -451.213% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -846.836% |
| CKD Bio Corp. | 170.76 Billion KRW | -398.841% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | -249.49% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -440.303% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -1880.105% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -974.159% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | -34.672% |
| Boryung Corporation | 373.1 Billion KRW | -128.305% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -309.143% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -313.757% |
| JW Lifescience Corporation | 96.44 Billion KRW | -783.239% |